|Dr. Jan-Anders Karlsson||CEO & Exec. Director||N/A||N/A||1955|
|Mr. Piers John Morgan||Chief Financial Officer||N/A||N/A||1966|
|Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA||Gen. Counsel||N/A||N/A||1967|
|Ms. Victoria Stewart||Director of Communications||N/A||N/A||N/A|
|Dr. Peter Spargo||Sr. VP of Chemistry Manufacturing & Controls||N/A||N/A||1962|
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler formulation and a pressurized metered-dose inhaler formulation, which are in Phase II clinical trials. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Verona Pharma plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.